Company Overview

Biodesix, Inc. is a U.S.-based diagnostics company focused on developing and commercializing blood-based proteomic and genomic tests primarily for lung disease, with a strong emphasis on lung cancer. The company operates within the precision diagnostics and oncology diagnostics industries, serving physicians, health systems, biopharmaceutical companies, and clinical researchers. Its core value proposition centers on providing minimally invasive tests that support clinical decision-making across the lung cancer care continuum, from early risk assessment to treatment selection.

The company’s primary revenue drivers are its proprietary diagnostic tests, including the Nodify Lung® test portfolio for pulmonary nodule assessment and the VeriStrat® test for therapy guidance in advanced lung cancer. Biodesix differentiates itself through its integrated proteomics, genomics, and bioinformatics platform, combined with a CLIA-certified laboratory infrastructure. Biodesix was founded in 2005 and has evolved from a proteomics research-focused organization into a commercial-stage diagnostics company, completing its initial public offering in 2021.

Business Operations

Biodesix operates as a single reportable operating segment, generating revenue primarily from clinical testing services and, to a lesser extent, biopharmaceutical services. Clinical testing revenue is driven by physician-ordered diagnostic tests processed through the company’s internally operated, CLIA-certified laboratory. The Nodify Lung® tests are used to help assess malignancy risk in patients with indeterminate pulmonary nodules, while VeriStrat® is used to inform treatment decisions for patients with advanced non-small cell lung cancer.

Operations are primarily U.S.-based, with all commercial testing performed domestically, while selected services and collaborations support global pharmaceutical research programs. Biodesix controls its proprietary mass spectrometry-based proteomic technologies, bioinformatics algorithms, and assay development capabilities. The company has established collaborations with biopharmaceutical companies for biomarker discovery, clinical trial support, and companion diagnostic development, though no material joint ventures have been disclosed in public filings.

Strategic Position & Investments

Biodesix’s strategy focuses on expanding adoption of its lung diagnostics through increased physician awareness, expanded payer coverage, and continued clinical evidence generation. Growth initiatives include extending the clinical utility of the Nodify Lung® portfolio, advancing next-generation genomic and multi-omic assays, and integrating real-world evidence to support guideline inclusion and reimbursement. The company also emphasizes leveraging its diagnostic platform to support drug development partnerships in oncology.

Investment activity has primarily centered on internal research and development rather than large-scale acquisitions. Biodesix has selectively invested in enhancing laboratory automation, data analytics, and assay development to support scalable growth. Its strategic positioning is reinforced by participation in emerging precision medicine approaches, including blood-based diagnostics that reduce reliance on invasive biopsy procedures. Data on additional material acquisitions or minority equity investments is inconclusive based on available public sources.

Geographic Footprint

Biodesix is headquartered in Louisville, Colorado, and conducts the majority of its operations within the United States. Its clinical laboratory operations, sales force, and administrative functions are domestically concentrated, reflecting the U.S.-centric nature of its reimbursement and regulatory strategy. The company’s tests are marketed primarily to U.S. pulmonologists, oncologists, and integrated healthcare systems.

Internationally, Biodesix maintains a limited footprint, primarily through collaborations with global biopharmaceutical companies and participation in multinational clinical studies. While its diagnostic tests are not broadly commercialized outside the United States, the company’s technologies and data have been utilized in research and drug development efforts with international scope. There is no public disclosure of material foreign subsidiaries or large-scale international laboratory operations.

Leadership & Governance

Biodesix is led by an executive team with experience in diagnostics, life sciences, and healthcare commercialization. Leadership emphasizes evidence-based medicine, disciplined commercialization, and the integration of advanced analytics into routine clinical care. The company is governed by a board of directors with backgrounds spanning biotechnology, diagnostics, finance, and public company governance.

Key executives include:

• Scott Hutton – President and Chief Executive Officer
• Chris Scott – Chief Financial Officer
• Nate Dolan – Chief Commercial Officer
• David Goodsaid – Chief Medical Officer
• Trevor Johnson – Chief Technology Officer

The leadership team’s strategic vision centers on establishing Biodesix as a standard-of-care diagnostics provider in lung disease by combining scientific rigor, clinical validation, and payer-aligned commercialization strategies.